These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10641981)

  • 1. Possible drug-associated pancreatitis after paclitaxel-cremophor administration.
    Mills KM; Johnson DM; Middlebrooks M; Burton GV
    Pharmacotherapy; 2000 Jan; 20(1):95-7. PubMed ID: 10641981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL).
    De Giorgi U; Rosti G; Monti M; Frassineti GL; Marangolo M
    Ann Oncol; 2003 Oct; 14(10):1588-9. PubMed ID: 14504063
    [No Abstract]   [Full Text] [Related]  

  • 3. Paclitaxel-induced pancreatitis: a case report.
    Hoff PM; Valero V; Holmes FA; Whealin H; Hudis C; Hortobagyi GN
    J Natl Cancer Inst; 1997 Jan; 89(1):91-3. PubMed ID: 8978416
    [No Abstract]   [Full Text] [Related]  

  • 4. Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel.
    Rischin D; Webster LK; Millward MJ; Linahan BM; Toner GC; Woollett AM; Morton CG; Bishop JF
    J Natl Cancer Inst; 1996 Sep; 88(18):1297-301. PubMed ID: 8797769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cross-reactivity of polysorbate 80 and cremophor: A case report.
    Bibera MAT; Lo KMK; Steele A
    J Oncol Pharm Pract; 2020 Jul; 26(5):1279-1281. PubMed ID: 31955702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel in a novel formulation containing less Cremophor EL as first-line therapy for advanced breast cancer: a phase II trial.
    Chao TC; Chu Z; Tseng LM; Chiou TJ; Hsieh RK; Wang WS; Yen CC; Yang MH; Hsiao LT; Liu JH; Chen PM
    Invest New Drugs; 2005 Mar; 23(2):171-7. PubMed ID: 15744594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.
    Gelderblom H; Mross K; ten Tije AJ; Behringer D; Mielke S; van Zomeren DM; Verweij J; Sparreboom A
    J Clin Oncol; 2002 Jan; 20(2):574-81. PubMed ID: 11786588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.
    Heney M; Alipour M; Vergidis D; Omri A; Mugabe C; Th'ng J; Suntres Z
    Can J Physiol Pharmacol; 2010 Dec; 88(12):1172-80. PubMed ID: 21164564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alternative formulations of paclitaxel.
    Terwogt JM; Nuijen B; Huinink WW; Beijnen JH
    Cancer Treat Rev; 1997 Mar; 23(2):87-95. PubMed ID: 9225960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of paclitaxel-induced pancreatitis.
    Kumar DM; Sundar S; Vasanthan S
    Clin Oncol (R Coll Radiol); 2003 Feb; 15(1):35. PubMed ID: 12602552
    [No Abstract]   [Full Text] [Related]  

  • 11. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer.
    Lee KS; Chung HC; Im SA; Park YH; Kim CS; Kim SB; Rha SY; Lee MY; Ro J
    Breast Cancer Res Treat; 2008 Mar; 108(2):241-50. PubMed ID: 17476588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study.
    Szebeni J; Muggia FM; Alving CR
    J Natl Cancer Inst; 1998 Feb; 90(4):300-6. PubMed ID: 9486816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between paclitaxel and necrotic pancreatitis.
    McMahon MA; Kearns G; McCaffrey J; Grogan L
    Ir Med J; 2006 Oct; 99(9):281. PubMed ID: 17144240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer.
    Smorenburg CH; ten Tije AJ; Verweij J; Bontenbal M; Mross K; van Zomeren DM; Seynaeve C; Sparreboom A
    Eur J Cancer; 2003 Jan; 39(2):196-202. PubMed ID: 12509952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
    O'Connor TL; Kossoff E
    Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes.
    Mielke S; Sparreboom A; Mross K
    Eur J Cancer; 2006 Jan; 42(1):24-30. PubMed ID: 16293411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Br J Clin Pharmacol; 2005 Mar; 59(3):325-34. PubMed ID: 15752379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
    Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumonitis related to treatment with paclitaxel.
    Goldberg HL; Vannice SB
    J Clin Oncol; 1995 Feb; 13(2):534-5. PubMed ID: 7844618
    [No Abstract]   [Full Text] [Related]  

  • 20. Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.
    Loos WJ; Szebeni J; ten Tije AJ; Verweij J; van Zomeren DM; Chung KN; Nooter K; Stoter G; Sparreboom A
    Anticancer Drugs; 2002 Aug; 13(7):767-75. PubMed ID: 12187334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.